美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Lonafarnib	Capsule			Develop a dissolution method			2023/09/15
Loperamide HCl	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Loperamide HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Loperamide HCl	Oral Suspension	II (Paddle)	25	0.01 N HCl	900	10, 20, 30, 45, 60, 75 and 90	2015/06/25
Loperamide HCl	Tablet (Chewable)	II (Paddle)	50	0.2 M Acetate Buffer, pH 4.7	500	5, 10, 15, 20 and 30	2015/06/25
Loperamide HCl/Simethicone	Tablet (Chewable)	II (Paddle)	50	0.2 M Acetate Buffer, pH 4.7	500	5, 10, 15, 20 and 30	2023/02/09
Loperamide HCl/Simethicone	Tablet	II (Paddle)	75	0.1N HCl	500	10, 15, 20, 30 and 45	2015/08/27
Lopinavir/Ritonavir	Tablet (Combination)			Refer to USP			2015/01/15
Lopinavir/Ritonavir	Capsule (Soft-Gelatin)	II (Paddle)	50	Tier 1: 0.05 M Polyoxyethylene 10 Lauryl Ether with 10 mM Sodium Phosphate monobasic (pH 6.8); Tier II: same as above with NMT 1750 USP units/L of Pancreatin	900	10, 15, 30 and 45	2007/06/18
Loratadine	Tablet (Chewable)	II (paddle)	50	0.1 N HCl	500	15, 30, 45 and 60	2008/07/14
Loratadine	Tablet (Orally Disintegrating)	I (Basket)	50	SGF without enzyme	900	2, 4, 6 and 10	2008/07/14
Loratadine	Capsule (Soft-Gelatin)	II (Paddle) with sinker	75	Tier I: 0.1N HCl with 0.1% Tween 20. Tier II: 0.1N HCl with 0.1% Tween 20 with addition of pepsin (as per USP).	900	10, 20, 30, 45 and 60	2013/02/28
Loratadine/Pseudoephedrine Sulfate (10 mg /240 mg)	Tablet (Extended Release)	I (Basket)	75	900 mL 0.1 N HCl for one hour, then replace the medium with 900 mL 0.05 M phosphate buffer at pH6.8 containing 0.01% sodium lauryl sulfate.	900	Loratadine:10, 15, 20, 30 and 45; Pseudoephedrine: 1, 2, 4, 8, 12, 16, 18 and 24 hours	2010/08/05
Loratadine/Pseudoephedrine Sulfate (5 mg /120 mg)	Tablet (Extended Release)	II (Paddle)	50	900 mL 0.1 N HCl for one hour, then replace with 900 mL 0.05 M phosphate buffer at pH 8.2 containing 0.01% sodium lauryl sulfate	900	Loratadine:15, 20, 30, 45, 60 and 90; Pseudoephedrine: 1, 2, 4, 8, 12 and 16 hours	2010/08/05
Lorazepam	Capsule (Extended Release)	I (Basket)	100	Acid Stage: 0.1N HCl; Buffer stage: Sodium Phosphate Buffer, pH 7.4	Acid stage: 700; Buffer stage: 1000	Acid stage: 0.5, 1 and 2 hours; Buffer stage: 0.5, 1, 2, 4, 6, 8, 12, 16, 20, and 24 hours	2022/05/12
Lorazepam	Tablet			Develop a dissolution method			2024/01/03
Lorcaserin HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Lorcaserin HCl	Tablet (Extended Release)	I (Basket)	100	0.1 N HCl (deaerated)	900	1, 2, 4, 5, 8 12, 16 and 20 hours	2016/10/20
Losartan Potassium	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Loteprednol Etabonate	Ophthalmic Suspension			Develop a method to characterize in vitro release			2016/06/30